Coronary Artery Disease
Conditions
Brief summary
The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes study ever.
Detailed description
CONFIRM2 is a retrospective and prospective, open-label, international, multicenter observational registry designed to evaluate associations between CCTA imaging findings and clinical presentation (cross-sectional) and their ability to predict mortality and major adverse cardiac events (longitudinal) in patients with chronic CAD.
Interventions
None listed
Sponsors
Cleerly, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>18 years * Undergoing clinically indicated CCTA with \>64-detector row CT * Signed informed consent, including of release of medical information, long term follow-up and Health Insurance Portability and Accountability Act (HIPAA) documentation
Exclusion criteria
* Individuals unable to provide informed consent * Non-cardiac illness with life expectancy \< 2 years * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Coronary CT Angiography EvaluatioN For Clinical Outcomes | June 2020- June 2022 | Examined the totality of information visualized by coronary CT angiography (CCTA) for optimal refinement of prognostic risk stratification |
Countries
United States
Contacts
STUDY_CHAIRJames K Min, MD
Cleerly, Inc.
STUDY_CHAIRUdo Hoffmann, MD
Cleerly, Inc.
Outcome results
None listed